{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T15:36:49Z","timestamp":1769873809959,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1038\/ncpgasthep0693","type":"journal-article","created":{"date-parts":[[2007,1,18]],"date-time":"2007-01-18T13:20:56Z","timestamp":1169126456000},"page":"S3-S9","source":"Crossref","is-referenced-by-count":4,"title":["Customizing treatment to patient populations"],"prefix":"10.1038","volume":"4","author":[{"suffix":"Jr","given":"Robert S","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFncpgasthep0693_CR1","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958\u2013965","journal-title":"Lancet"},{"key":"BFncpgasthep0693_CR2","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975\u2013982","journal-title":"N Engl J Med"},{"key":"BFncpgasthep0693_CR3","doi-asserted-by":"publisher","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","volume":"140","author":"SJ Hadziyannis","year":"2004","unstructured":"Hadziyannis SJ et al. (2004) Peginterferon-\u03b12a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346\u2013355","journal-title":"Ann Intern Med"},{"key":"BFncpgasthep0693_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1126\/science.282.5386.103","volume":"282","author":"AU Neumann","year":"1998","unstructured":"Neumann AU et al. (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-\u03b1 therapy. Science 282: 103\u2013107","journal-title":"Science"},{"key":"BFncpgasthep0693_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jhep.2005.04.009","volume":"43","author":"P Ferenci","year":"2005","unstructured":"Ferenci P et al. (2005) Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)\/ribavirin. J Hepatol 43: 425\u2013433","journal-title":"J Hepatol"},{"key":"BFncpgasthep0693_CR6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1053\/j.gastro.2006.05.016","volume":"131","author":"JM Sanchez-Tapias","year":"2006","unstructured":"Sanchez-Tapias JM et al. (2006) Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastorenterology 131: 451\u2013460","journal-title":"Gastorenterology"},{"key":"BFncpgasthep0693_CR7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1468-1293.2006.00365.x","volume":"7","author":"S Hopkins","year":"2006","unstructured":"Hopkins S et al. (2006) Role of individualization of hepatitis C virus (HCV) therapy duration in HIV\/HCV-coinfected individuals. HIV Med 7: 248\u2013254","journal-title":"HIV Med"},{"key":"BFncpgasthep0693_CR8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/135965350601100409","volume":"11","author":"D Fuster","year":"2006","unstructured":"Fuster D et al. (2006) Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV\/HCV-coinfected patients with no early virological response. Antivir Ther 11: 473\u2013482","journal-title":"Antivir Ther"},{"key":"BFncpgasthep0693_CR9","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/hep.20467","volume":"40","author":"O Dalgard","year":"2004","unstructured":"Dalgard O et al. (2004) Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 40: 1260\u20131265","journal-title":"Hepatology"},{"key":"BFncpgasthep0693_CR10","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1053\/j.gastro.2005.05.008","volume":"129","author":"M von Wagner","year":"2005","unstructured":"von Wagner M et al. (2005) Peginterferon-\u03b12a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129: 522\u2013527","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0693_CR11","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa042608","volume":"325","author":"A Mangia","year":"2005","unstructured":"Mangia A et al. (2005) Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 325: 2609\u20132617","journal-title":"N Engl J Med"},{"key":"BFncpgasthep0693_CR12","doi-asserted-by":"crossref","unstructured":"Shiffman ML (2006) Peginterferon alfa-2a (Pegasys) plus ribavirin (Copegus) for 16 or 24 weeks in patients with HCV genotype 2 or 3. Final results of the ACCELERATE trial. Presented at 41st Annual Meeting of the European Association for the Study of the Liver: 2006 April 26\u201330, Vienna, Austria","DOI":"10.1016\/S0168-8278(06)80734-8"},{"key":"BFncpgasthep0693_CR13","doi-asserted-by":"crossref","unstructured":"Berg T et al. (2006) Individualized treatment strategy with peginterferon alfa-2b (PEG-IFN ALFA) plus ribavirin according to early viral kinetics in hepatitis C virus (HCV) type 1 infected patients. Presented at: 41st Annual Meeting of the European Association for the Study of the Liver: 2006 April 26\u201330, Vienna, Austria","DOI":"10.1016\/S0168-8278(06)80559-3"},{"issue":"Suppl 1","key":"BFncpgasthep0693_CR14","first-page":"749A","volume":"42","author":"IM Jacobson","year":"2005","unstructured":"Jacobson IM et al. (2005) Weight-based ribavirin dosing increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): final results of the WIN-R study, a US community based trial. Hepatology 42 (Suppl 1): 749A","journal-title":"Hepatology"},{"key":"BFncpgasthep0693_CR15","unstructured":"Brown RS . Customizing treatment to patient populations. Presented at Treating Hepatitis C in Difficult-to-Treat Patients and Special Populations: 2006, 22 May, Los Angeles, CA"},{"issue":"Suppl 2","key":"BFncpgasthep0693_CR16","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/S0168-8278(06)80042-5","volume":"44","author":"RS Brown","year":"2006","unstructured":"Brown RS et al. (2006) Differences in treatment outcomes to antiviral therapy based on genotype and viral load in hepatitis C genotypes 2 and 3 in the WIN-R trial. J Hepatol 44 (Suppl 2): S20","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"BFncpgasthep0693_CR17","first-page":"P120","volume":"140","author":"N Afdhal","year":"2006","unstructured":"Afdhal N et al. (2006) The effect of liver fibrosis and cirrhosis on SVR in 4913 patients with hepatitis C: results from the WIN-R trial. Gastroenterology 140 (Suppl 2): P120","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"BFncpgasthep0693_CR18","doi-asserted-by":"publisher","first-page":"S273","DOI":"10.1016\/S0168-8278(06)80739-7","volume":"44","author":"Y Benhamou","year":"2006","unstructured":"Benhamou Y et al. (2006) The safety and efficacy of viramidine plus pegylated interferon alpha-2b versus ribavirin plus pegylated interferon alpha-2b in therapy-na\u00efve patients infected with HCV: phase 3 results. J Hepatol 44 (Suppl 2): S273","journal-title":"J Hepatol"},{"key":"BFncpgasthep0693_CR19","unstructured":"HCV Meta-analysis Working Group et al. (2005) Efficacy of weight-based PEG-IFN alfa-2b vs. fixed dose PEG-IFN alfa-2a + ribavirin regimens in treatment-na\u00efve chronic HCV patients: a cumulative meta-analysis of retrospective data from 6 clinic sites. Hepatology 42 (Suppl 1): 671A"},{"key":"BFncpgasthep0693_CR20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1590-8658(03)00376-1","volume":"35","author":"P Ferenci","year":"2003","unstructured":"Ferenci P (2003) Weight-based dosing of pegylated interferon-alpha in chronic hepatitis C: just a marketing 'gag'? Dig Liver Dis 35: 601\u2013606","journal-title":"Dig Liver Dis"},{"key":"BFncpgasthep0693_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1365-2893.2005.00709.x","volume":"13","author":"B Meyer-Wyss","year":"2006","unstructured":"Meyer-Wyss B et al. (2006) Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg\/kg) combined with ribavirin in interferon-naive patients with chronic hepatitis C and up to moderate fibrosis. J Viral Hepat 13: 457\u2013465","journal-title":"J Viral Hepat"},{"key":"BFncpgasthep0693_CR22","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1056\/NEJMoa032502","volume":"350","author":"AJ Muir","year":"2004","unstructured":"Muir AJ et al. (2004) Peginterferon alfa-2b ban ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350: 2265\u20132271","journal-title":"N Engl J Med"},{"key":"BFncpgasthep0693_CR23","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1002\/hep.20212","volume":"39","author":"LJ Jeffers","year":"2004","unstructured":"Jeffers LJ et al. (2004) Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39: 1702\u20131708","journal-title":"Hepatology"},{"key":"BFncpgasthep0693_CR24","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1053\/j.gastro.2006.06.008","volume":"131","author":"HS Conjeevaram","year":"2006","unstructured":"Conjeevaram HS et al. (2006) Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131: 470\u2013477","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"BFncpgasthep0693_CR25","first-page":"125","volume":"40","author":"I Jacobson","year":"2004","unstructured":"Jacobson I et al. (2004) Weight based ribavirin dosing improves virologic response in HCV-infected genotype 1 African-Americans (AA) compared to flat dose ribavirin with peginterferon alfa-2B combination therapy. Hepatology 40 (Suppl 1): 125","journal-title":"Hepatology"},{"key":"BFncpgasthep0693_CR26","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.jhep.2004.02.007","volume":"40","author":"S Zeuzem","year":"2004","unstructured":"Zeuzem S et al. (2004) Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 40: 993\u2013999","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"BFncpgasthep0693_CR27","doi-asserted-by":"publisher","first-page":"A768","DOI":"10.1016\/S0016-5085(03)83881-7","volume":"124","author":"G Teuber","year":"2003","unstructured":"Teuber G et al. (2003) Retreatment with pegylated interferon-alpha2b plus ribavirin in patients with chronic hepatitis C not responding to a previous antiviral treatment with standard interferons combined with ribavirin. Gastroenterology 124 (Suppl 1): A768","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"BFncpgasthep0693_CR28","doi-asserted-by":"publisher","first-page":"A714","DOI":"10.1016\/S0016-5085(03)83604-1","volume":"124","author":"IM Jacobson","year":"2003","unstructured":"Jacobson IM et al. (2003) Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: a trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers: final results. Gastroenterology 124 (Suppl 1): A714","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"BFncpgasthep0693_CR29","doi-asserted-by":"publisher","first-page":"A702","DOI":"10.1016\/S0016-5085(03)83551-5","volume":"124","author":"M Sulkowski","year":"2003","unstructured":"Sulkowski M et al. (2003) Pharmacokinetics, pharmacodynamics, and antiviral response in patients with chronic hepatitis C infection on methadone maintenance therapy receiving Peginterferon (40KD) alfa-2a (Pegasys). Gastroenterology 124 (Suppl 1): A702\u2013703","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"BFncpgasthep0693_CR30","doi-asserted-by":"publisher","first-page":"A783","DOI":"10.1016\/S0016-5085(03)83957-4","volume":"124","author":"EJ Lawitz","year":"2003","unstructured":"Lawitz EJ et al. (2003) Pegylated interferon alfa 2b and ribavirin for hepatitis C patients who were nonresponders to previous therapy. Gastroenterology 124 (Suppl 1): A783\u2013784","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"BFncpgasthep0693_CR31","first-page":"A-684","volume":"123","author":"JB Gross","year":"2005","unstructured":"Gross JB et al. (2005) Double-dose peginterferon alfa-2b plus weight-based ribavirin for re-treatment of African-American non-responders with hepatitis C. Gastroenterology 123 (Suppl 2): A-684","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0693_CR32","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1053\/j.gastro.2004.01.014","volume":"126","author":"ML Shiffman","year":"2004","unstructured":"Shiffman ML et al. (2004) Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126: 1015\u20131023","journal-title":"Gastroenterology"},{"issue":"Suppl 4","key":"BFncpgasthep0693_CR33","first-page":"102A","volume":"40","author":"C Leevy","year":"2004","unstructured":"Leevy C et al. (2004) Interim results of a pilot study of the combination of type 1 (IFN Alfacon 1) and type 2 (IFN Gamma 1B) interferons in chronic hepatitis C patients who have failed to respond to peg-interferon alfa 2a plus ribavirin. Hepatology 40 (Suppl 4): 102A","journal-title":"Hepatology"}],"container-title":["Nature Clinical Practice Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpgasthep0693.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpgasthep0693","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpgasthep0693.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:04:48Z","timestamp":1684440288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpgasthep0693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":33,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["BFncpgasthep0693"],"URL":"https:\/\/doi.org\/10.1038\/ncpgasthep0693","relation":{},"ISSN":["1743-4378","1743-4386"],"issn-type":[{"value":"1743-4378","type":"print"},{"value":"1743-4386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}